|
| 37358937 | Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas. | Neurooncol Adv | 2023 |
| 37585199 | Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome. | JAMA Dermatol | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37722990 | Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience. | | 2023 |
| 36831683 | DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. | Cancers (Basel) | 2023 |
| 36966049 | Treatment of glioblastoma using MRIdian® A3i BrainTx⿢: Imaging and treatment workflow demonstration. | | 2023 |
| 36638331 | Key Clinical Principles in the Management of Glioblastoma. | | 2023 |
| 36562121 | Erratum to: Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review. | | 2023 |
| 35137228 | Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. | Neuro Oncol | 2022 |
| 35740612 | Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. | Cancers | 2022 |
| 36322100 | Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review. | Neuro-Oncology | 2022 |
| 35402914 | Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies. | Neuro-Oncology Advances | 2022 |
| 36382108 | Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. | Neurooncol Adv | 2022 |
| 35296750 | Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. | Sci Rep | 2022 |
| 34795049 | Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study. | Neurology | 2022 |
| 35093015 | Relationship between insurance status and interhospital transfers among cancer patients in the United States. | BMC Cancer | 2022 |
| 34773051 | Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. | Sci Rep | 2021 |
| 32462883 | Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. | | 2021 |
| 33795827 | Hospitalization rates for complications due to systemic therapy in the United States. | Scientific Reports | 2021 |
| 33898990 | Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. | Neurooncol Adv | 2021 |
| 33500827 | Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma. | | 2021 |
| 34302487 | SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. | Neuro Oncol | 2021 |
| 33919580 | Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. | Current Oncology | 2021 |
| 33333043 | Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum. | Clinica Chimica Acta | 2021 |
| 34988451 | Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. | Neurooncol Adv | 2021 |
| 34400582 | Contemporary Neuroscience Core Curriculum for Medical Schools. | Neurology | 2021 |
| 35201504 | Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. | Discov Oncol | 2021 |
| 32804776 | Inpatient Palliative Care Use Among Critically III Brain Metastasis Patients in the United States. | American Journal of Clinical Oncology: Cancer Clinical Trials | 2020 |
| 32377912 | A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. | International Journal of Colorectal Disease | 2020 |
| 31990757 | Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016. | American Journal of Clinical Oncology: Cancer Clinical Trials | 2020 |
| 31702782 | Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. | Neuro Oncol | 2020 |
| 32602020 | Early imaging marker of progressing glioblastoma: a window of opportunity. | J Neurooncol | 2020 |
| 31314136 | Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. | Cancer | 2019 |
| 32042476 | EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host. | Neurology: Clinical Practice | 2019 |
| 31456142 | Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. | J Neurooncol | 2019 |
| 30952114 | First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. | Journal of Neurosurgery: Pediatrics | 2019 |
| 28495808 | Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. | Oncologist | 2017 |
| 28425764 | BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. | CNS oncology | 2017 |
| 27695598 | Electrographic Correlates of Plateau Waves in Patients With Leptomeningeal Metastases. | Neurohospitalist, The | 2016 |
| 26860632 | A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. | CNS Oncol | 2016 |
| 26643807 | A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. | J Neurooncol | 2016 |
| 27615706 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. | CNS oncology | 2016 |
| 26285768 | A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. | J Neurooncol | 2015 |
| 25907263 | Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis. | Clinical Neuropathology | 2015 |
| 25864100 | Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. | Journal of Neuro-Oncology | 2015 |
| 25098701 | Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. | J Neurooncol | 2014 |
| 23934175 | cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. | J Neurooncol | 2013 |
| 22928601 | Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. | Brain Pathol | 2013 |
| 23846349 | LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. | Oncotarget | 2013 |
| 24022427 | A glioblastoma neurosphere line with alternative lengthening of telomeres. | Acta Neuropathol | 2013 |